Quick Answer
Rein Therapeutics, Inc. reported Operating Income of -$50.63 million for fiscal year 2025.
Rein Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$50.63M | +22.2% |
| 2024 | -$65.11M | -300.0% |
| 2023 | -$16.28M | +41.1% |
| 2022 | -$27.65M | -3.9% |
| 2021 | -$26.61M | -29.8% |
| 2020 | -$20.50M | +31.6% |
| 2019 | -$29.96M | +6.1% |
| 2018 | -$31.90M | -38.7% |
| 2017 | -$23.01M | -26.6% |
| 2016 | -$18.17M | -40.9% |
| 2015 | -$12.89M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$5.49M | +9.5% | +20.1% |
| June 30, 2025 | -$6.87M | +24.0% | -22.5% |
| March 31, 2025 | -$5.61M | +22.2% | +7.6% |
| September 30, 2024 | -$6.07M | -206.2% | +32.8% |
| June 30, 2024 | -$9.04M | -353.8% | -25.5% |
| March 31, 2024 | -$7.21M | -43.8% | -263.3% |
| September 30, 2023 | -$1.98M | +69.4% | +0.5% |
| June 30, 2023 | -$1.99M | +75.2% | +60.2% |
- Rein Therapeutics, Inc. showed an increase of +22.2% in Operating Income compared to the prior fiscal year.
- Over the 2015–2025 period, Rein Therapeutics, Inc.’s operating income has declined by 292.8% (from -$12.89 million to -$50.63 million).
- The most recent figure is from Rein Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: